Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Portugal: An Uptick In Life Science VC Funding

Executive Summary

An international VC, Vesalius Biocapital, is to invest in start-up life sciences and biotech companies in the western European country that is developing an entrepreneurial ecosystem.

You may also be interested in...



Vesalius’s “Proven Investment Strategy” Reflected In Largest Fund Close To Date

European fund manager Vesalius has closed its third fund with €120m. Its managers believe their strategy of investing in maturing companies has been the key to attracting commitments, including from the European Investment Fund.

Austerity in Portugal drops drug bill 21%, drives parallel exports, hospital debt

Market conditions in Portugal are continuing to deteriorate as cost cutting has fuelled parallel exports and hospitals owe companies increasingly more money, APIFARMA, the local R&D-based pharmaceutical industry association, has warned.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC099548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel